title: Will purple become the new orange? The new FDA purple book for biologics: what does the future hold?
authors: Dilworth IP, LLC, 2 Corporate Drive, Suite 206, Trumbull, CT 06611, USA.
authors: Anthony D
authors: AD
authors: Sabatelli
authors: Cambria J
authors: CJ
authors: Alpha-Cobb
mesh_terms: D001688:Biological Products; D017277:Drug Approval; D016568:Drugs, Generic; D010330:Patents as Topic; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D001688:Biological Products; D016568:Drugs, Generic
keywords: BPCIA; Hatch–Waxman; biologics; biosimilars; generics; interchangeables; orange book; purple book